Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) was the target of unusually large options trading activity on Thursday. Stock investors acquired 1,116 call options on the stock. This represents an increase of approximately 1,792% compared to the average daily volume of 59 call options.
Several brokerages have recently commented on TTPH. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. HC Wainwright boosted their target price on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, November 6th. BMO Capital Markets boosted their target price on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. Finally, Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $15.15.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $6.21 on Tuesday. The stock has a market cap of $319.28, a P/E ratio of -2.16 and a beta of 2.51. Tetraphase Pharmaceuticals has a 1-year low of $3.57 and a 1-year high of $9.93.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total value of $52,762.50. Following the completion of the sale, the insider now owns 8,750 shares in the company, valued at approximately $52,762.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director L Patrick Gage bought 3,880 shares of the company’s stock in a transaction dated Wednesday, November 29th. The stock was purchased at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now directly owns 38,880 shares in the company, valued at approximately $250,776. The disclosure for this purchase can be found here. 5.50% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in the stock. Canada Pension Plan Investment Board grew its holdings in shares of Tetraphase Pharmaceuticals by 54.4% during the 3rd quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock valued at $17,470,000 after purchasing an additional 900,000 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Tetraphase Pharmaceuticals by 32.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock worth $9,998,000 after acquiring an additional 360,552 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Tetraphase Pharmaceuticals during the 3rd quarter worth approximately $7,915,000. Northern Trust Corp grew its holdings in Tetraphase Pharmaceuticals by 4.8% during the 2nd quarter. Northern Trust Corp now owns 886,765 shares of the biopharmaceutical company’s stock worth $6,323,000 after acquiring an additional 40,668 shares during the last quarter. Finally, Numeric Investors LLC grew its holdings in Tetraphase Pharmaceuticals by 1,363.3% during the 2nd quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock worth $5,379,000 after acquiring an additional 702,812 shares during the last quarter. 58.15% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/09/stock-traders-buy-large-volume-of-call-options-on-tetraphase-pharmaceuticals-ttph.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
What are top analysts saying about Tetraphase Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tetraphase Pharmaceuticals and related companies.